Biogen (BIIB) Tops Q4 EPS by 25c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $216.12 +3.04%
EPS Growth %: -41.5%
Financial Fact:
Total revenues: 2.96B
Today's EPS Names:
CRMT, More
EPS Growth %: -41.5%
Financial Fact:
Total revenues: 2.96B
Today's EPS Names:
CRMT, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $6.99, $0.25 better than the analyst estimate of $6.74. Revenue for the quarter came in at $3.53 billion versus the consensus estimate of $3.39 billion.
GUIDANCE:
Biogen sees FY2019 EPS of $28.00-$29.00, versus the consensus of $28.02. Biogen sees FY2019 revenue of $13.6-13.8 billion, versus the consensus of $13.63 billion.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen expects $164M R&D charge to hit Q2 2026 earnings
- RBC Capital Upgrades GEA Group AG (G1A:GR) (GEAGY) to Outperform
- Rivian raises 2026 delivery outlook after Q2 results top guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
